Antagonism of anti-inflammatory drugs on bradykinin-induced increase of capillary permeability.
D000085:Acetates / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D001920:Bradykinin / Q000037:antagonists & inhibitors*; D001949:Bretylium Compounds / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects*; D002740:Chlorothiazide / Q000494:pharmacology; D005260:Female; D006591:Hexobarbital / Q000494:pharmacology; D008464:Mecamylamine / Q000494:pharmacology; D008528:Mefenamic Acid / Q000494:pharmacology; D010208:Papaverine / Q000494:pharmacology; D010653:Phenylbutazone / Q000494:pharmacology*; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D012980:Sodium Salicylate / Q000494:pharmacology*; D014520:Urethane / Q000494:pharmacology; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
D000085:Acetates; D000893:Anti-Inflammatory Agents; D001949:Bretylium Compounds; D062367:ortho-Aminobenzoates; D008528:Mefenamic Acid; D014520:Urethane; D008464:Mecamylamine; D002740:Chlorothiazide; D012110:Reserpine; D006591:Hexobarbital; D010208:Papaverine; D010653:Phenylbutazone; D001241:Aspirin; D001920:Bradykinin; D012980:Sodium Salicylate